PHP
ANGO icon

Parkman Healthcare Partners’s AngioDynamics ANGO Stock Holding History

Parkman Healthcare Partners’s Portfolio ANGO Stock Details ANGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-87,969
Closed -$2.43M – 81
2021
Q4 		$2.43M Buy
+87,969
New +$2.43M 0.54% 51

Other funds holding ANGO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Parkman Healthcare Partners's ANGO Position: Q1 2022 in Review

Parkman Healthcare Partners sold out of AngioDynamics (ANGO) in Q1 2022, closing a stake of 87,969 shares — an estimated $2.43M sold.

Parkman Healthcare Partners first reported a position in ANGO in Q4 2021 and held it in 1 quarter. The position peaked at $2.43M in Q4 2021. 144 funds tracked by Wall St. Rank hold ANGO as of Q1 2022.

  • Parkman Healthcare Partners reported no remaining AngioDynamics position as of Q1 2022 after selling out during the quarter.
  • Parkman Healthcare Partners sold 87,969 AngioDynamics shares in Q1 2022, an estimated $2.43M.
  • Parkman Healthcare Partners first reported a position in AngioDynamics in Q4 2021 and held it in 1 quarter.
  • Parkman Healthcare Partners's AngioDynamics position peaked at $2.43M in Q4 2021.
  • 144 funds tracked by Wall St. Rank held AngioDynamics as of Q1 2022.

Based on Parkman Healthcare Partners's 13F filing for Q1 2022, filed 13 May 2022.